首页> 外文期刊>Breast cancer >Complete Remission of Recurrent Breast Cancer with Multiple Liver Metastases after Oral Capecitabine and Injected Trastuzumab
【24h】

Complete Remission of Recurrent Breast Cancer with Multiple Liver Metastases after Oral Capecitabine and Injected Trastuzumab

机译:口服卡培他滨和注射曲妥珠单抗后完全复发的多发性肝转移性乳腺癌

获取原文
获取外文期刊封面目录资料

摘要

A 32-year-old woman underwent modified radical mastectomy for right breast cancer (invasive ductal carcinoma, f, INF β, v0, ly1, pT2, pN1, M0, Stage II B ER (±), PR (-), Her2 (3+)) in June 2003, and received postoperative systemic adjunctive chemotherapy using epirubicin combined with cyclophosphamide, followed by paclitaxel. In August 2004, after a disease-free interval of 14 months, liver metastasis appeared, and therefore from September 2004, combination chemotherapy with oral capecitabine (2,400 mg/day) and injected trastuzumab (120 mg/week) was started. After 3 cycles, all the metastases responded and this marked response has been maintained for 16 months. This therapy is currently being continued (19 cycles), and no serious side effects have been encountered.Capesitabine and trastuzumab combination therapy is effective for recurrent breast cancer showing overexpression of HER2 and resistance to taxane, and can be considered as a first-line therapy for this purpose. It is anticipated that many cases treated with this regimen will be reported and discussed in the near future.
机译:一名32岁妇女接受了改良的乳腺癌根治术(右导管癌,f,INFβ,v0,ly1,pT2,pN1,M0,II期ER(±),PR(-),Her2( 3+)),并于2003年6月接受表柔比星联合环磷酰胺联合紫杉醇的术后全身辅助化疗。 2004年8月,在无病间隔14个月后,出现了肝转移,因此从2004年9月开始,开始联合口服卡培他滨(2,400 mg /天)和曲妥珠单抗(120 mg /周)联合化疗。 3个周期后,所有转移灶均应答,并且此明显应答已维持16个月。该疗法目前仍在继续(19个周期),尚未遇到严重的副作用。卡培他滨和曲妥珠单抗联合疗法对复发性乳腺癌有效,表现出HER2过表达和对紫杉烷的耐药性,可以被认为是一线治疗以此目的。预计不久后将报道和讨论使用该方案治疗的许多病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号